Letter--Corrected Net Health Benefit Calculations for Enzalutamide Using ASCO Value Framework Guidelines and NCCN Evidence Blocks

Scott Flanders; Bruce Brown; Marjan Massoudi; Neil Schultz; Krishnan Ramaswamy

doi:10.18553/jmcp.2017.23.11.1202

Letter--Corrected Net Health Benefit Calculations for Enzalutamide Using ASCO Value Framework Guidelines and NCCN Evidence Blocks

J Manag Care Spec Pharm. 2017 Nov;23(11):1202. doi: 10.18553/jmcp.2017.23.11.1202.

Authors

Scott Flanders¹, Bruce Brown², Marjan Massoudi³, Neil Schultz⁴, Krishnan Ramaswamy⁵

Affiliations

¹ 1 Senior Director, Health Economics and Outcomes Research-Oncology Astellas Pharma.
² 2 Senior Medical Director, Oncology Astellas Pharma.
³ 3 Associate Director, Health Economics and Outcomes Research Astellas Pharma.
⁴ 4 Senior Manager, Health Economics and Outcomes Research-Oncology Astellas Pharma.
⁵ 5 Senior Director, Health Economics and Outcomes Research Pfizer.

Abstract

This research was funded by Astellas Pharma and Medivation, which was acquired by Pfizer in 2016. Astellas Pharma and Medivation are the co-developers of enzalutamide. Flanders, Brown, Massoudi, and Schultz are employees of Astellas Pharma. Ramaswamy is an employee of Pfizer and holds stock in Johnson & Johnson. Flanders holds stock in Johnson & Johnson, AbbVie, and Abbott Labs.

Publication types

Letter

MeSH terms

Antineoplastic Agents
Benzamides
Clinical Trials as Topic / standards
Evidence-Based Medicine / standards*
Humans
Male
Nitriles
Phenylthiohydantoin / analogs & derivatives*
Phenylthiohydantoin / therapeutic use
Practice Guidelines as Topic / standards*
Prostatic Neoplasms, Castration-Resistant / diagnosis
Prostatic Neoplasms, Castration-Resistant / drug therapy*

Substances

Antineoplastic Agents
Benzamides
Nitriles
Phenylthiohydantoin
enzalutamide